$1,030,000 of JOHNSON & JOHNSON SERVICES INC lobbying was just disclosed, from Q2 of 2025, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"- H.R. 1539, Medical Device Electronic Labeling Act, regarding all provisions - S. 266, the Dr. Lorna Breen Health Care Provider Protection Reauthorization Act, regarding all provisions - H.R. 946 ORPHAN Cures Act, regarding all provisions - S.864, HELP Copays Act, regarding all provisions - H.R. 2214, Delinking Revenue from Unfair Gouging (DRUG) Act, regarding all provisions - H.R. 1492/S. 832, Ensuring Pathways to Innovative Cures (EPIC) Act - S. 1954, Biosimilar Red Tape Elimination Act, regarding all provisions - H.R.2527, Early Detection of Vision Impairments for Children Act of 2025, regarding all provisions - PL117-169 The Inflation Reduction Act, regarding all provisions related to drug pricing and implementation Issues related to - direct to consumer advertising - clinical trial modernization - biosimilars - cardiovascular health - 340B - Heart Recovery Awareness Day & H.Res. 1301, designating February 20th Heart Recovery Awareness Day - obesity treatments - Issues related to stroke care - S. 1040, Drug Competition Enhancement Act, regarding all provisions - S. 1041, Affordable Prescriptions for Patients Act of 2025, regarding all provisions - S. 1097, Interagency Patent Coordination and Improvement Act of 2025, regarding all provisions Issues related to - intellectual property, including S. 1040, a bill to amend the Federal Trade Commission Act to prohibit product hopping - Medication Affordability and Patent Integrity Act - patent thickets Issues related to - H.R. 1109, the Litigation Transparency Act of 2025, and transparency in domestic third-party litigation funding - the Protecting Our Courts from Foreign Manipulation Act, and transparency in foreign third-party litigation funding - Issues related to the SUPPORT Act Issues related to - artificial intelligence - data privacy - cybersecurity - robotics Issues related to - OECD proposals on global tax & implementation and/or related Presidential executive orders - corporate tax provisions in TCJA including in 2025 reconciliation bills - Issues related to Veterans Administration and Veterans Health Administration procurement and contracting processes for medical technology"
You can find more data on corporate lobbying on Quiver Quantitative.
JNJ Congressional Stock Trading
Members of Congress have traded $JNJ stock 21 times in the past 6 months. Of those trades, 10 have been purchases and 11 have been sales.
Here’s a breakdown of recent trading of $JNJ stock by members of Congress over the last 6 months:
- REPRESENTATIVE SCOTT FRANKLIN sold up to $50,000 on 06/16.
- REPRESENTATIVE PETE SESSIONS sold up to $50,000 on 06/12.
- REPRESENTATIVE LLOYD DOGGETT has traded it 2 times. They made 2 purchases worth up to $30,000 on 06/10, 03/04 and 0 sales.
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 4 times. They made 2 purchases worth up to $100,000 on 05/30, 03/31 and 2 sales worth up to $30,000 on 04/29, 01/24.
- REPRESENTATIVE JEFFERSON SHREVE has traded it 3 times. They made 2 purchases worth up to $100,000 on 03/05, 02/24 and 1 sale worth up to $100,000 on 05/12.
- REPRESENTATIVE MARJORIE TAYLOR GREENE purchased up to $15,000 on 05/05.
- REPRESENTATIVE BRUCE WESTERMAN has traded it 2 times. They made 1 purchase worth up to $15,000 on 03/03 and 1 sale worth up to $15,000 on 04/21.
- REPRESENTATIVE JOSH GOTTHEIMER has traded it 4 times. They made 2 purchases worth up to $30,000 on 01/24, 01/21 and 2 sales worth up to $30,000 on 04/09, 03/07.
- REPRESENTATIVE ROBERT BRESNAHAN sold up to $15,000 on 04/08.
- REPRESENTATIVE JULIE JOHNSON sold up to $15,000 on 04/01.
- REPRESENTATIVE GEORGE WHITESIDES sold up to $250,000 on 03/24.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
JNJ Insider Trading Activity
JNJ insiders have traded $JNJ stock on the open market 4 times in the past 6 months. Of those trades, 0 have been purchases and 4 have been sales.
Here’s a breakdown of recent trading of $JNJ stock by insiders over the last 6 months:
- JOHN C REED (EVP, Innovative Medicine, R&D) sold 19,137 shares for an estimated $3,129,829
- JOSEPH J WOLK (Exec VP, CFO) sold 13,015 shares for an estimated $2,002,878
- ROBERT J DECKER (VP Corporate Controller) sold 6,999 shares for an estimated $1,160,994
- TIMOTHY SCHMID (EVP, WW Chair, MedTech) sold 403 shares for an estimated $62,928
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
JNJ Hedge Fund Activity
We have seen 1,812 institutional investors add shares of JNJ stock to their portfolio, and 2,004 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- JPMORGAN CHASE & CO added 15,277,413 shares (+39.4%) to their portfolio in Q1 2025, for an estimated $2,533,606,171
- GAMMA INVESTING LLC removed 7,166,000 shares (-99.3%) from their portfolio in Q2 2025, for an estimated $1,094,606,500
- PRICE T ROWE ASSOCIATES INC /MD/ removed 6,177,098 shares (-37.9%) from their portfolio in Q1 2025, for an estimated $1,024,409,932
- ROBERT WOOD JOHNSON FOUNDATION removed 6,167,294 shares (-71.0%) from their portfolio in Q1 2025, for an estimated $1,022,784,036
- BANK OF AMERICA CORP /DE/ added 4,972,642 shares (+22.1%) to their portfolio in Q1 2025, for an estimated $824,662,949
- BANK OF NEW YORK MELLON CORP added 4,842,582 shares (+26.4%) to their portfolio in Q1 2025, for an estimated $803,093,798
- DZ BANK AG DEUTSCHE ZENTRAL GENOSSENSCHAFTS BANK, FRANKFURT AM MAIN added 4,354,793 shares (+493.7%) to their portfolio in Q1 2025, for an estimated $722,198,871
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
JNJ Analyst Ratings
Wall Street analysts have issued reports on $JNJ in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- RBC Capital issued a "Outperform" rating on 07/17/2025
- UBS issued a "Buy" rating on 07/17/2025
- Raymond James issued a "Outperform" rating on 04/16/2025
- Goldman Sachs issued a "Buy" rating on 04/09/2025
To track analyst ratings and price targets for JNJ, check out Quiver Quantitative's $JNJ forecast page.
JNJ Price Targets
Multiple analysts have issued price targets for $JNJ recently. We have seen 11 analysts offer price targets for $JNJ in the last 6 months, with a median target of $172.0.
Here are some recent targets:
- Matt Miksic from Barclays set a target price of $176.0 on 07/17/2025
- Tim Anderson from B of A Securities set a target price of $175.0 on 07/17/2025
- Danielle Antalffy from UBS set a target price of $190.0 on 07/17/2025
- Vamil Divan from Guggenheim set a target price of $167.0 on 07/17/2025
- Terence Flynn from Morgan Stanley set a target price of $176.0 on 07/17/2025
- Shagun Singh from RBC Capital set a target price of $185.0 on 07/17/2025
- David Risinger from Leerink Partners set a target price of $153.0 on 05/13/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
